课题基金 / 基金详情

项目摘要

项目成果

JOHN L NITISS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Topoisomerase II (Top2) is the target of a wide range of active anti-cancer agents. Drugs targeting Top2 are widely used and active agents, but a detailed understanding of how they act against the enzyme has proven elusive. Clinically active Top2 targeting agents lead to enzyme mediated DNA damage, and are referred to as Top2 poisons. Detailed information about the action of Top2 poisons has the potential for leading to safer and more active anti-cancer drugs. An important model system for understanding the biological and biochemical properties of DNA topoisomerases is the yeast Saccharomyces cerevisiae. The genetic tools available in this organism also make it a powerful system for studying mechanisms of action of anti-cancer drugs targeting topoisomerases. Yeast Top2 has also been the enzyme of choice for structural studies of eukaryotic Top2. The overall goal of this project is to apply all of the tools available with the yeast system to obtain a detailed understanding of how Top2 poisons interact with the enzyme, and how Top2 drug interactions lead to Top2 mediated DNA damage. We propose a combination of genetic, biochemical and structural approaches to understand the action of Top2 poisons on their target enzymes. Genetic studies will allow the isolation and characterization of novel drug hypersensitive mutants of Top2. These studies will increase our understanding of how Top2 poisons bind to the enzyme and generate enzyme-mediated DNA damage. Assays for assessing drug action, including measurements of drug affinity and enzyme mediated DNA cleavage will be applied to test how drug hypersensitivity occurs in the mutant proteins. We also plan to study a novel mutant of human Top2 that mimics the action of Top2 poisons in the absence of drug. Studies with this mutant will provide a biochemical understanding of Top2 mediated DNA damage in the context of the overall reaction cycle. Finally, the drug hypersensitive mutants will provide necessary reagents for structural studies that will attempt to solve the structure of drug:protein:DNA ternary complexes. The proposed experiments will be useful in the design of new agent targeting Top2, and may suggest more effective use of Top2 targeting drugs that are in clinical use.
期刊论文(54)
专著(0)
科研奖励(0)
会议论文
Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
双二氧代哌嗪右雷佐生与人 DNA 拓扑异构酶 II α 结合的分析:结合减少是耐药机制。
DOI: 10.1021/bi034557d
发表时间: 2003
期刊: Biochemistry.
影响因子: --
作者: [Renodon-Corniere,Axelle, Jensen,LarsH, Nitiss,JohnL, Jensen,PeterB, Sehested,Maxwell]
通讯作者: Sehested,Maxwell
DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
DNA 拓扑异构酶 II 是酿酒酵母中双二氧代哌嗪衍生物 ICRF-159 和 ICRF-193 的分子靶标。
DOI: --
发表时间: 1995
期刊: Cancer research.
影响因子: --
作者: [Ishida,R, Hamatake,M, Wasserman,RA, Nitiss,JL, Wang,JC, Andoh,T]
通讯作者: Andoh,T
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
探讨双二氧代哌嗪类似物中接头取代基对野生型和突变型人拓扑异构酶 II α 活性的作用。
DOI: 10.1124/mol.63.5.1159
发表时间: 2003
期刊: Molecular pharmacology
影响因子: 3.6
作者: [Renodon-Cornière,Axelle, Sørensen,TinaK, Jensen,PeterB, Nitiss,JohnL, Søkilde,Birgitte, Sehested,Maxwell, Jensen,LarsH]
通讯作者: Jensen,LarsH
DOI: 10.1074/jbc.m804058200
发表时间: 2008
期刊: The Journal of biological chemistry
影响因子: --
作者: [Rogojina,AnnaT, Nitiss,JohnL]
通讯作者: Nitiss,JohnL
32
    Genome Instability induced in cancer cells carrying mutations in Type II topoisomerases
    Genome Instability induced in cancer cells carrying mutations in Type II topoisomerases
    Novel approaches for studying topoisomerase 2 targeting anti-cancer drugs
    DNA REPAIR AND ANTITOPOISOMERASE DRUG EFFECTS
    海外基金